COME L'ESPERIENZA DEL RIANIMATORE PUÒ INTEGRARSI CON QUELLA DEL CARDIOLOGO, DEL CARDIOCHIRURGO, DEL NEFROLOGO NELLA GESTIONE DEL PAZIENTE IN FASE CRITICA

MILANO, Atahotel Executive 28-29 Novembre 2011



Come si misura la funzione renale Come si previene l'IRA Le soluzioni di rimpiazzo. I diuretici L'ecografia nella valutazione dello stato volemico

Luca Doroni





Cardiothoracic Anaesthesia & Intensive Care Medicine University Hospital of Pisa, Italy



Perioperative Acute Renal Failure

• Incidence 5-17%



 The mortality rate exceeds 50% and depends upon the kind of surgery

Uchino S, Kellum JA, Bellomo R et al. Acute renal failure in critically ill patients: a multinational, multicenter study. *The Journal of the American Medical Association* 2005 Aug 17; **294**(7): 813–818. Chertow GM, Burdick E, Honour M et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. *Journal of the American Society of Nephrology: JASN* 2005 Nov; **16**(11): 3365–3370.

Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized Patients


Glenn M. Chertow,* Elisabeth Burdick,[†] Melissa Honour,[†] Joseph V. Bonventre,[‡] and David W. Bates[†]

Table 1 | Hospital-acquired AKI: mortality and cost associated with selected changes in SCr

Increase in SCr (mg/dl)		Multivariable OR (95% CI)	Area under ROC curve	Increase in total cost	
0.3		4.1 (3.1–5.5)	0.84	\$4,886	
0.5		6.5 (5.0-8.5)	0.86	\$4,886 \$7,499	
1.0		9.7 (7.1–13.2)	0.84	\$13,200	
2.0		16.4 (10.3–26)	0.83	\$22,023	

AKI, acute kidney injury; CI, confidence interval; OR, odds ratio; ROC, receiving operating characteristic; SCr, serum creatinine.

Postoperative AKI and mortality



Kheterpal S, Tremper KK, Englesbe MJ, et al. Anesthesiology. 2007;107:892-902.

 Table 3 Actiological factors associated with renal dysfunction following cardiopulmonary bypass

Non-bypass factors

- 1. Significant surgical trauma.
- 2. Shed blood management.
- 3. Anaesthesia—increases the pro-inflammatory cytokines (IL-1, IL-8, TNFα, also IL-1ra, CD11b, HLA-DR expression).
- 4. Heparin-protamine interactions activate complement, also pro-cytokines.

Patient-related factors

- 1. Genotype—apolipoprotein E4 allele.
- 2. Pre-morbid conditions-congestive heart failure; diabetes mellitus.
- 3. Drugs—use of β -agonists/antagonists; use of ACEI.

Bypass related

- 1. Contact activation.
- 2. Ischaemia.
- 3. Endotoxin translocation from the gut to the kidney.

British Journal of Anaesthesia 95 (1): 20-32 (2005)

TABLE 2. Clinical conditions causing high risk for cardiac surgeryassociated acute kidney injury

Clinical conditions

```
Preoperative estimated GFR < 60 \text{ mL/min/1.73 m}^2
```

```
Preoperative left ventricular ejection fraction < 35\%
```

Emergency surgery

Cardiogenic shock

Acute myocardial infarction in the week preceding surgery

Left main coronary artery disease

Receiving diuretic or inotropic therapy for decompensated heart failure CPB time > 3 h

GFR, Estimated glomerular filtration rate; SCr, serum creatinine; CPB, cardiopulmonary bypass.

The Journal of Thoracic and Cardiovascular Surgery • May 2010



What is ARF?

Creatinine ∆0.1	mg/dL
-----------------	-------

Creatinine increase >0.5 mg/dL

Creatinine ≥ 1.7 mg/dL

Creatinine \geq 1.5 mg/dL

Creatinine ≥ 2 mg/dL

Creatinine \ge 2.1 mg/dL and x 2

Creatinine > 3.2 mg/dL or x 2

Creatinine >5 mg/dL or K⁺ > 5.5 mmol/L

Creatinine increase $\geq 25\%$

Creatinine increase $\geq 50\%$

Creatinine increase $\geq 100\%$

Δ Creatinine 72h >0µmol/L

Creatinine \ge 177µmol/L and Δ >62µmol/L

∆ Creatinine 72h >25µmol/L

Creatinine > 200 μ mol/L (2.36 mg/dL) Δ Creatinine 72h >44 μ mol/L

 Δ Creatinine 72h >50µmol/L

 Δ Creatinine 72h >100µmol/L

Cockcroft-Gault Creatinine Clearance: 30–60 ml/min

△ Cockcroft-Gault 72h <0%

∆ Cockcroft-Gault Creatinine Clearance 72h <-15%


∆ Cockcroft-Gault Creatinine Clearance 72hr <-25%

∆ Cockcroft-Gault Creatinine Clearance 72hr<-50%

MDRD: 50% change in GFR

Hoste EA et al Int J Art if Organs 2008 : 31 (2); 158-65

SCr not a sensitive marker of acute changes !!



SCr varies with age,
BSA, status hydration

• SCr not proportional to renal function

• SCr not accurate in the acute setting but in the steady-state

RIFLE criteria for classification of ARF



		GFR Criteria	UO Criteria	
R	Risk	S _{Cr} increased 1.5× <i>or</i> GFR decreased by > 25%	UO < 0.5 ml/kg/hr for 6 hr	
ī	Injury	S _{Cr} increased 2× <i>or</i> GFR decreased by > 50%	UO < 0.5 ml/kg/hr for 12 hr	High Sensitivity
F	Failure	S _{Cr} increased 3× <i>or</i> GFR decreased by 75% <i>or</i> S _{Cr} ≥ 4 mg/dl in setting of acute rise of ≥ 0.5 mg/dl	UO < 0.3 ml/kg/hr for 24 hr <i>or</i> Anuria for 12 hr	Oliguria
L	Loss		Persistent ARF = complete loss of kidney function for > 4 wk	
E	End Stage		End-stage kidney disease (> 3 mo)	

Bellomo R, Defining, quantifying, and classifying acute renal failure, Crit Care Clin. 2005; 21:223–237

Definitions of Acute Kidney Injury

Acute I	Acute Kidney Injury Network Criteria			RIFLE Criteria		
	Creatinine/ GFR	Urine Output		Creatinine/ GFR	Urine Output	
Stage 1	Increased Cr 0.3mg/dL or Cr 150% baseline	UOP<0.5 mL/kg/h for>6h	Risk (R)	Increased Cr $1.5 \times \text{or}$ GFR decreased < 25%	UOP <0.5mL/ kg/h for >6h	
Stage 2	Cr 200%- 300% baseline	UOP<0.5 mL/kg/h for >12h	Injury (I)	Increased Cr 2×or GFR decreased <50%	UOP <0.5mL/ kg/h for >12h	
Stage 3	Cr>300% of baseline or >4mg/dL with 0.5mg/ dL acute increase	UOP<0.3 mL/kg/h for 24 h or anuria for 12h	Failure (F)	Increased Cr $3 \times \text{or GFR}$ decreased <75% or Cr >4mg/ dL with 0.5mg/dL acute increase	UOP <0.3mL/kg/ h for 24h or anuria for 12 h	
			Loss (L) ESKD (E)	Persistent ARF Persistent loss >		

R204-R212.


Ideal characteristics for AKI biomarkers

- Noninvasive
- Highly sensitive for early detection
- Specific for AKI
- Allow monitoring of patient
- Rapidly quantifiable
- Reproducible using standard assays

- Allow for risk stratification
- Allow for identification of AKI subtypes
- Stable production rate
- Circulating levels unaffected by pathologic changes
- Freely filtered at glomerulus without tubular reabsorption/secretion







Seminars in Cardiothoracic and Vascular Anesthesia / Vol. 12, No. 4, December 2008






Figure 3. Using biomarkers to predict outcomes and target early interventions following acute kidney injury to improve outcomes.

Seminars in Cardiothoracic and Vascular Anesthesia / Vol. 12, No. 4, December 2008



New Markers: Cystatin C

Produced by all nucleated cells, is freely filtered by the glomerulus, reabsorbed by the proximal tubule, and is not secreted by renal tubules.

> Nephrol Dial Transplant (2010) 1 of 7 doi: 10.1093/ndt/gfq176

Original Article




Rapid detection of acute kidney injury by plasma cystatin C in the intensive care unit

Maryam Nejat¹, John W. Pickering¹, Robert J. Walker² and Zoltán H. Endre¹

New Markers: IL-18




Proinflammatory cytokine produced by caspase-1involved in the pathogenesis of ARF.In a case-control trial IL-18 was a predictor of AKIand mortality in ARDS patients.





New Markers: NGAL



NGAL levels increase in the blood and urine within only a few hours after the injury.

Clinical studies have found that NGAL functions as an early marker of renal function across a wide variety of clinical settings including CKD and cardiac surgery.


tensive Care Med OI 10.1007/s00134-010-1887-4	ORIGINAL	Clinical Utility of Neutrophil Gelatinase–Associated	1	In-Depth Review	
		Lipocalin as an Early Marker for Acute Kidney Injury	od. Dation	Blood Purif 2010;29:357-365 DOI: 10,1159/000309421	
ohan Mårtensson fax Bell nders Oldner hengyuan Xu er Venge	Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury	J Thorac Cardiovasc Surg 2010:139:1101-6	Serum and Urina Kidney Injury	nary Biomarkers of Acute	
laes-Roland Martling		В	arbara Lisowska-Mviak		





Perioperative AKI




- Causes of AKI are classified as prerenal, renal, or postrenal in origin.
- ATN is the most common cause of perioperative AKI.
- The pathogenesis of ATN involves both ischemia and inflammation with cell death due to both necrosis and apoptosis.










net filtration pressure = 55 mm Hg – 30 mm Hg – 15 mm Hg = 10 mm Hg

 $P_H - \pi - P_{fluid}$

Pathophysiology: pre-renal AKI



- AKI is due to absolute or relative hypoperfusion
- If hypoperfusion is not rapidly corrected ATN occurs





Reduction of circulating volume

Haemorrhage



Plasma loss

Dehydration






Third space collection






MAP & CO reduction




Myocardial ischemia

Arrhythmias




Shock







Renal autoregulation





Acute tubular necrosis

The most frequent AKI (70%)

Ischemic


• Toxic







Ischemic ATN: Pathophysiology



Devarajan P J Am Soc Nephrol 17: 1503–1520

Ischemic ATN: Pathophysiology

12



Perioperative renal protection*


Dean R. Jones M.D., FRCPC Assistant Professor

H. Thormas Lee^{*} M.D., Ph.D. Assistant Professor Department of Anesthesiology, Callege of Physicians and Surgeons of Columbia University New York, NY 10032, USA

- Ischemia and inflammation lead to both vascular and tubular derangements.
- Tubules structural changes: loss of cell polarity, shedding of the brush border into the tubular lumen, tubular
 obstruction, and cell death



Ctrl



 Ischemic

 14
 12
 4
 3

 15
 13
 11
 7
 5
 2
 3

 16
 9
 10
 8
 6
 2
 3

 17
 18
 1
 1
 1
 1




Figure 10 3D image of mitochondria in control and ischemically injured tubular cells.





J. Clin. Invest. 119:1275–1285 (2009).





Toxic acute tubular necrosis














Perioperative toxic ATN: exogenous

- Antibiotics (aminoglycoside, amfotericine)
- Cytostatic (ciclosporine)
- Contrast media










 Variable: from mild creatinine 1 to need for CRRT


- Serum creatinine behaviour:
 - Increase within 24 h in 60% of cases
 - peak between 3rd and 5th day
 - Recovery in 1-2 weeks





Antonio I. Bartorelli • Giancarlo Marenzi








Patient related risk factors


- Age > 70
- CRF 7-27 %
- Dehydratation
- Diabetes & CRF 33-48 %
- Hypovolemia
- CHF
- Nephrotic syndrome
- Nephrotoxic drugs








Contrast related factors



- Hydrofilia
- Repeated administration within 72 h







What to do?

Treatment of AKI



Hydratation

Loop Diuretics

Dopamine (low doses)

Fenoldopam

N-Acetyl Cystein

Teophylline

Atrial Natriuretic Peptide

Strategies that are likely to be effective Isotonic hydration (IV route) Once-daily dosing of aminoglycosides Use of lipid formulations of amphotericin B Use of iso-osmolar nonionic contrast media Strategies of unknown efficacy NAC Theophylline Low-dose recombinant ANP (in cardiac surgical patients) Strategies that are not effective Loop diuretics Dopamine and dopamine receptor agonists ANPs

Prophylactic hemofiltration


Perioperative renal protection

Best Practice & Research Clinical Anaesthesiology Vol. 22, No. I, pp. 193–208, 2008

Prevention of perioperative acute renal failure: what works?

Best Practice & Research Clinical Anaesthesiology Vol. 18, No. 1, pp. 91–111, 2004

COSA ABBIAMO A DISPOSIZIONE



IL caso J. Boldt 89 lavori «Retracted»

Molte metanalisi contenevano i dati del Prof. Boldt

Un nuovo inizio; una cascata di nuovi studi

COSA USIAMO:

Intensive Care Med (2004) 30:2222-2229 DOI 10.00070/00154-004-2415-1

ORIGINAL

Frédérique Schortgen Nicolas Deyr Laurent Brochard for the CRYCO Study Group Preferred plasma volume expanders for critically ill patients: results of an international survey

IN EUROPA

NEL MONDO

	Crystalloids		Colloids				
	Isotonic	Hypertonic	Starches	Gelatins	Albumin	Plasma	Dextrans
France (n=162)	72	0	51	40	6	2	0
Germany (n=63)	84	0	81	19	5	6	0
United Kingdom (n=40)	60	0	35	68	5	0	0
The Netherlands (n=35)	91	2	66	46	3	3	0
Italy (n=33)	88	0	54	42	6	18	0
European countries (n=517)	80	2	58	35	5	5	3
Non-European countries (n=60)	82	0	25	35	22	10	5

IN SCANDINAVIA




Fig. 1. The preferred colloid in 73 Scandinavian intensive can units. More than one answer could be given. HES, hydroxyethy starch; ICUs, intensive care units.

Alderson P et al, Cochrane 2000

•18 trial su albumina o plasma o altre frazioni plasmatiche vs/ (641 pz),

•7 trials su amido idrossietilico vs/ (197 pz),

•4 trial su gelatina modificata vs/ (95 pz),

•8 trials su destrano vs/ 668 pz.

Conclusion

"There is no evidence from randomised controlled trials that resuscitation with colloids reduces the risk of death compared to crystalloids in patients with trauma, burns and following surgery.


As colloids are not associated with an improvement in survival, and as they are more expensive than crystalloids, it is hard to see how their continued use in these patient types can be justified outside the context of randomised controlled


Cosa scegliere

Sicuramente nel paziente critico lungo degente in ICU c'è bisogno di "programmare" un terapia infusionale <u>valutando bene</u> quale sono i rischi e i benefici di ciascun fluido.



In attesa risultati studio Albios 2008-2012







IVC distensibility

ΔIVC = 100 x	(IVCinsp – IVCexp)				
	IVCinsp				
Δ IVC >	18%				



Interventions for protecting renal

function in the perioperative period

The Cochrane Database of Systematic Reviews 2010 Issue 5, Copyright © 2010

There is no evidence from available RCTs that any of the measures used to protect patients' kidneys during the perioperative period are beneficial

including: dopamine and its analogues, diuretics, Ca⁺ channel blockers, ACE inhibitors or hydration fluids.

There is no difference in morbidity (renal failure) or mortality following the various perioperative interventions.





Decreased duration of RRT and increased UO

no improvement in mortality or independence from RRT in AKI patients.

Crit Care Resusc. 2007 Mar;9(1):60-8.

Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis.

Bagshaw SM, Delaney A, Haase M, Ghali WA, Bellomo R. Department of Intensive Care, Austin Hospital, Melbourne, VIC, Australia. sean.bagshaw@austin.org.au

Therapy: dopamine



'Renal dose' dopamine does not protect patients from AKI and has numerous side effects.

Is There Still a Place for Dopamine in the Modern Intensive Care Unit?

Yves A. Debaveye, MD, and Greet H. Van den Berghe, MD, PhD Department of Intensive Care Medicine, Catholic University of Leuven, Leuven, Belgium

Therapy: fenoldopam mesylate



A recent meta-analysis of 16 randomized studies found reduced the risk of AKI, RRT, and in-hospital death.

Beneficial Impact of Fenoldopam in Critically III Patients With or at Risk for Acute Renal Failure: A Meta-Analysis of Randomized Clinical Trials JCVA 2010, march

Giovanni Landoni, MD, Giuseppe G.L. Biondi-Zoccai, MD, James A. Tumlin, MD, Tiziana Bove, MD, Monica De Luca, MD, Maria Grazia Calabrò, MD, Marco Ranucci, MD, and Alberto Zangrillo, MD



Perioperative management

• Individualize renal perfusion: a lower MAP >65 mmHg

• Expand intravascular volume

Prevention of perioperative acute renal failure: what works?

Best Practice & Research Clinical Anaesthesiology Vol. 18, No. 1, pp. 91–111, 2004

Perioperative management



- Avoid hypotensive anesthesia in patients at risk of AKI
- Lower pressures for laparoscopic procedures or gasless laparoscopy should be considered for pts at high risk of AKI
- Antihypertensive medications and NSAID's should be held in patients without adequate intravascular volume
- Adjust perioperative antibiotics based on Cr. clearance

COME L'ESPERIENZA DEL RIANIMATORE PUÒ INTEGRARSI CON QUELLA DEL CARDIOLOGO, DEL CARDIOCHIRURGO, DEL NEFROLOGO NELLA GESTIONE DEL PAZIENTE IN FASE CRITICA

MILANO, Atahotel Executive 28-29 Novembre 2011



- AKI is associated with increased mortality
- AKI should be looked at as a "preventable" rather than "treatable" clinical entity
- The only management strategy proven to be of value consists in providing adequate volume expansion, adequate renal perfusion, and avoiding nephrotoxins